SALIX PHARMACEUTCLS (NASDAQ:SLXP)
26.91
0.06 (0.22%)
| SALIX PHARMACEUTCLS (NASDAQ:SLXP) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $26.97 | 52 Week High | $29.91 | ||
| Open | $26.89 | 52 Week Low | $6.14 | ||
| Day High | $27.20 | P/E | N/A | ||
| Day Low | $26.54 | EPS | $-0.98 | ||
| Volume | 171,420 | ||||
| More SLXP Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ALXA | 3 | HDY | 2 |
| KERX | 2 | KNX | 1 |
| ORCT | 1 | CALP | 1 |
| ELOS | 1 | HWCC | 1 |
| NTT | 1 | SRE | 1 |
| WN | 1 | PTV | 1 |
Entities who have mentioned SLXP
- Tracinda Corp. | View Related Stories »
- Kirk Kerkorian | View Related Stories »
- Jefferies & Co | View Related Stories »
- Piper Jaffray | View Related Stories »
- 13G | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Credit Suisse | View Related Stories »
- Steven A. Cohen | View Related Stories »
- Matrix USA | View Related Stories »
- Banc of America | View Related Stories »
- SAC Capital | View Related Stories »
- Daniel Loeb | View Related Stories »
- Options | View Related Stories »
- Roth Capital | View Related Stories »
- JPMorgan | View Related Stories »
- Argus | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Soleil Securities | View Related Stories »
- Citi | View Related Stories »
- Hedge Funds | View Related Stories »
- JMP Securities | View Related Stories »
- UBS | View Related Stories »
- HSBC | View Related Stories »
- Trading Radar | View Related Stories »
- Greenlight Capital | View Related Stories »
View All Major News StreetInsider.com Major News for SLXP
- Salix Pharmaceuticals (SLXP) Reports Mixed Q2 Results
- Salix Pharma (SLXP) Reports Mixed Q1 Earnings; Guides Q2
- Salix Pharma (SLXP) Reports Q4 Loss of $0.22; Guides Q1
View All ReportsStreetInsider.com Reports on SLXP
- Summer Street Initiates Coverage of Salix Pharmaceuticals (SLXP) with a Buy
- Notable Analyst Rating Changes 02/01: BIDU, ALV, G, ARG, ASH Upgraded; CPF, M, LZ, COGT, WCRX Downgraded
- Jefferies & Co Initiates Coverage on Salix Pharmaceuticals (SLXP) with a Buy
- Oppenheimer Upgrades Salix Pharmaceuticals (SLXP) to Outperform
- Salix (SLXP) February volatility at 58, April at 73 into FDA meeting
StreetInsider Reports on SLXP by Category
View All BlogsBlogs on SLXP
- Analyst Upgrades, Downgrades and Initiations: AMLN, CI, CTXS, HSY, KRA, TSCO, TXN ...
- Biotech’s 2009 Stealth Small Cap Rally
- FDA Calendar Extreme Trades: 85 Single Digit Stocks
- Salix: Approval of Rifaximin Would Help Drive Long-Term Growth
- Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
View All FilingsSEC Filings on SLXP
- Form 4 SALIX PHARMACEUTICALS For: Feb 04 Filed by: Sirgo Mark A
- Form SC 13G SALIX PHARMACEUTICALS Filed by: BlackRock Inc.
- Form SC 13G SALIX PHARMACEUTICALS Filed by: TOCQUEVILLE ASSET MANAGEMENT LP
- Form 4 SALIX PHARMACEUTICALS For: Jan 06 Filed by: Sirgo Mark A
- Form 4 SALIX PHARMACEUTICALS For: Dec 23 Filed by: Forbes William P
Comments on SLXP
No comments are currently available.
